KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Intangibles (2016 - 2025)

Historic Intangibles for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Q3 2025 value amounting to $111.6 million.

  • Acadia Pharmaceuticals' Intangibles rose 578.12% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year increase of 578.12%. This contributed to the annual value of $119.8 million for FY2024, which is 8290.12% up from last year.
  • Acadia Pharmaceuticals' Intangibles amounted to $111.6 million in Q3 2025, which was up 578.12% from $114.3 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Intangibles' 5-year high stood at $119.8 million during Q4 2024, with a 5-year trough of $369000.0 in Q2 2021.
  • For the 4-year period, Acadia Pharmaceuticals' Intangibles averaged around $81.4 million, with its median value being $105.5 million (2024).
  • Its Intangibles has fluctuated over the past 5 years, first plummeted by 8001.08% in 2021, then soared by 8290.12% in 2024.
  • Quarter analysis of 4 years shows Acadia Pharmaceuticals' Intangibles stood at $369000.0 in 2021, then skyrocketed by 17647.97% to $65.5 million in 2023, then soared by 82.9% to $119.8 million in 2024, then dropped by 6.82% to $111.6 million in 2025.
  • Its Intangibles was $111.6 million in Q3 2025, compared to $114.3 million in Q2 2025 and $117.1 million in Q1 2025.